Overview
MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects
Status:
Completed
Completed
Trial end date:
2007-10-01
2007-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of the study is to measure how much nitroglycerin or its metabolites may be found in the bloodstream when MQX-503 or an FDA approved Nitroglycerin ointment 2% USP is applied to the skin of healthy subjects.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
MediQuest TherapeuticsTreatments:
Nitroglycerin
Criteria
Inclusion Criteria:- Healthy volunteers 18 - 70 years of age.
- Subjects able to give written informed consent and comply with study requirements.
- Subjects willing and able to safely discontinue all current prescription therapies.
- Subjects who will agree not to participate in other clinical trials.
- Negative pregnancy test in fertile females and agreement to use effective
contraception throughout the study.
Exclusion Criteria:
- Persons who would be put at risk by discontinuing prescription therapies.
- Subjects with a known allergy to nitroglycerin.
- Subjects who have a condition or issue that would adversely affect the application of
study medication, study evaluations or the subject's ability to comply with the
protocol.
- Subjects who recently experienced myocardial infarction, uncontrolled congestive heart
failure, unstable angina, uncontrolled hypotension or uncontrolled hypertension.
- Subjects who have participated in a study of an investigational drug within two weeks
of visit 1.
- Subjects who have screening lab values that are out of range or are considered
clinically significant by the investigator.
- Subjects who have had major abdominal, thoracic, or vascular surgery within 6 months
of visit 1.
- Subjects with non-epithelialized skin lesions or interfering skin conditions at the
time of screening in the area where study medication is to be applied.
- Pregnant or nursing women.
- Women of childbearing potential who are unwilling to comply with the contraceptive
requirements.